Clinical Kidney Journal, sfz164, doi: 10.1093/ckj/sfz164
In the original article, some of the AMH centile data were wrongly reproduced in Table 1. These have been corrected. In addition, reference 13 was included in error. It has been removed and all subsequent references have been renumbered.
Table 1.
Cohort demographics, serum AMH concentrations and age-corrected AMH centiles according to CKD stage
| Demographics and AMH results | All CKD | CKD 1 | CKD 2 | CKD 3a | CKD 3b | CKD 4–5 |
|---|---|---|---|---|---|---|
| n | 163 | 30 | 37 | 26 | 31 | 39 |
| Age (years) | 36.5 | 33.2 | 38.3 | 38.0 | 34.8 | 41.7 |
| (29.9–42.9) | (25.9–36.8) | (30.0–44.8) | (30.6–42.3) | (30.7–44.1) | (34.5–44.9) | |
| Ethnicity, n (%) | ||||||
| White European | 84 (62) | 16 (64) | 17 (63) | 16 (67) | 17 (63) | 18 (55) |
| Black | 30 (22) | 5 (20) | 5 (19) | 6 (25) | 5 (19) | 9 (27) |
| Southeast Asian | 22 (16) | 4 (16) | 5 (19) | 2 (8) | 5 (19) | 6 (18) |
| eGFR (mL/min/1.73 m2) | 51 (31–80) | 116 (109–140) | 72 (65–80) | 52 (48–56) | 38 (34–41) | 15 (9–23) |
| Renal disease aetiology, n (%) | ||||||
| Non-lupus glomerular disease | 42 (26) | 11 (37) | 9 (24) | 6 (23) | 9 (29) | 7 (18) |
| Lupus vasculitis | 28 (17) | 10 (33) | 3 (8) | 4 (15) | 3 (10) | 8 (21) |
| Hereditary/congenital | 21 (13) | 2 (7) | 11 (30) | 1 (4) | 2 (6) | 5 (13) |
| Reflux | 14 (9) | 0 (0) | 3 (8) | 2 (8) | 4 (13) | 5 (13) |
| Diabetic nephropathy | 13 (8) | 2 (7) | 1 (3) | 2 (8) | 4 (13) | 4 (10) |
| Hypertensive/renovascular | 8 (5) | 0 (0) | 2 (5) | 3 (12) | 2 (6) | 1 (3) |
| Other | 15 (9) | 0 (0) | 4 (11) | 3 (12) | 2 (6) | 6 (15) |
| Unknown | 22 (13) | 5 (17) | 4 (11) | 5 (19) | 5 (16) | 3 (8) |
| Renal transplant, n (%) | ||||||
| Functioning | 37 (23) | 1 (3) | 3 (8) | 10 (38) | 14 (45) | 9 (23) |
| Non-functioning | 1 (1) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (3) |
| Current dialysis, n (%) | 10 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 10 (56) |
| Haemodialysis | 7 (4) | 7 (39) | ||||
| Peritoneal dialysis | 3 (2) | 3 (17) | ||||
| Regular menstruation, n/N (%) | 35/51 (69) | 8/11 (73) | 5/8 (64) | 5/8 (64) | 8/12 (67) | 9/12 (75) |
| Oestrogen-containing drug use, n/N (%) | 9/133 (7) | 2/24 (8) | 5/30 (17) | 0/20 (0) | 0/25 (0) | 2/34 (6) |
| Progesterone-containing contraceptive use, n/N (%) | 25/131 (19) | 4/24 (17) | 5/29 (17) | 3/20 (15) | 7/25 (28) | 6/33 (18) |
| Serum AMH (pmol/L) | 6.33 (1.90–15.65) | 10.06 (4.62–20.73) | 6.02 (1.79–12.85) | 4.27 (1.44–8.79) | 8.89 (4.99–19.36) | 5.29 (1.27–14.77) |
| Serum AMH (ng/mL) | 0.88 (0.27–2.19) | 1.41 (0.65–2.90) | 0.84 (0.25–1.80) | 0.60 (0.20–1.23) | 1.25 (0.70–2.71) | 0.74 (0.18–2.07) |
| AMH centile | 19 (8–53) | 30 (4–55) | 28 (10–53) | 11 (4–31) | 24 (14–59) | 15 (7–60) |
| AMH predictive of low response to gonadotrophin stimulation (AMH ≤5.4 pmol/L), n (%)a | 95 (58) | 9 (30) | 18 (47) | 17 (65) | 8 (26) | 20 (51) |
Values are median (IQR) unless stated.
a
National Institute for Health and Care Excellence advise that AMH ≤5.4 pmol/L (Beckman-Coulter assay) is used to predict a low ovarian response to gonadotrophin stimulation [5].